<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">
LSX-Blog.png

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Vital signs in UK life sciences

In 2017, Professor Sir John Bell published the well-received Life Sciences ...

Read More

Rethinking the growth capital challenge in UK life...

Investors, entrepreneurs and deal makers in the UK life sciences industry m...

Read More

Artios Pharma’s £65m Series B to spur development ...

Key findings:

Read More

Evox Therapeutics raises £35.5m Series B to advanc...

Key learnings: UK biotech Evox Therapeutics recently announced its £35.5 mi...

Read More

Key challenges to scaling up early-stage investmen...

Access to venture capital and effective fundraising tactics are key to buil...

Read More

Brexit: finite uncertainty

One might think that planning for uncertainty is something that biotech fir...

Read More

Interview with Avacta Group's Alastair Smith

In this video, Donald Leggatt, Head of Investor Relations at London South E...

Read More

Growing opportunities in cannabinoid-based treatme...

In June 2018 it was announced that venture capital firm Casa Verde Capital,...

Read More

Make Brexit a non-issue for pharma

What is the recipe for keeping business momentum in clinical trials despite...

Read More

Technical notices for a ‘no-deal’ Brexit

The UK government issued a series of ‘technical notices’ on 23 August outli...

Read More

CMR Surgical prepares for commercialisation on the...

Key findings: In June 2018, surgical robotics company CMR Surgical raised $...

Read More

Exploring IP best practice in UK life sciences

In 2017, the East of England filed 623 patents via the European Patent Offi...

Read More

Add Your Response